Rondoni John
Known title: Chief Technology OfficerCIK: 0001932219
Associated companies
Transaction History
| INSP | ▼ Sell | Open Market | 2,641 | $114K | 5/15/2026 | View on chart |
| INSP | ▼ Sell | Open Market | 700 | $30K | 5/14/2026 | View on chart |
| INSP | ▲ Buy | Grant | 2,400 | $0 | 2/20/2026 | View on chart |
| INSP | ▼ Sell | Tax Withholding | 735 | $44K | 2/20/2026 | View on chart |
| INSP | ▲ Buy | Grant | 15,958 | $0 | 2/20/2026 | View on chart |
| INSP | ▼ Sell | Tax Withholding | 587 | $35K | 2/13/2026 | View on chart |
| INSP | ▼ Sell | Tax Withholding | 327 | $22K | 2/9/2026 | View on chart |
| INSP | ▼ Sell | Open Market | 109 | $11K | 1/9/2026 | View on chart |
| INSP | ▼ Sell | Open Market | 1,734 | $259K | 5/19/2025 | View on chart |
| INSP | ▼ Sell | Open Market | 2,287 | $424K | 3/3/2025 | View on chart |
| INSP | ▲ Buy | Grant | 3,296 | $0 | 2/24/2025 | View on chart |
| INSP | ▼ Sell | Tax Withholding | 1,009 | $188K | 2/24/2025 | View on chart |
| INSP | ▲ Buy | Grant | 5,076 | $0 | 2/13/2025 | View on chart |
| INSP | ▼ Sell | Open Market | 583 | $99K | 2/11/2025 | View on chart |
| INSP | ▼ Sell | Tax Withholding | 315 | $57K | 2/9/2025 | View on chart |
| INSP | ▼ Sell | Open Market | 58 | $12K | 1/7/2025 | View on chart |
| INSP | ▼ Sell | Open Market | 1,580 | $306K | 11/1/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 1,013 | $197K | 11/1/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 333 | $65K | 11/1/2024 | View on chart |
| INSP | ▲ Buy | Option Exercise | 5,802 | $412K | 11/1/2024 | View on chart |
| INSP | ▲ Buy | Option Exercise | 2,901 | $122K | 11/1/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 5,777 | $1.1M | 11/1/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 31 | $7K | 9/9/2024 | View on chart |
| INSP | ▲ Buy | Option Exercise | 5,000 | $355K | 8/22/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 1,201 | $227K | 8/22/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 3,799 | $722K | 8/22/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 825 | $160K | 3/22/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 3,062 | $595K | 3/22/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 500 | $98K | 3/22/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 52 | $9K | 2/29/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 2,255 | $404K | 2/29/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 80 | $14K | 2/29/2024 | View on chart |
| INSP | ▼ Sell | Open Market | 6,218 | $1.1M | 2/29/2024 | View on chart |
| INSP | ▲ Buy | Option Exercise | 8,000 | $17K | 2/15/2024 | View on chart |
| INSP | ▲ Buy | Grant | 2,694 | $0 | 2/9/2024 | View on chart |
| INSP | ▲ Buy | Option Exercise | 4,387 | $9K | 3/8/2023 | View on chart |
| INSP | ▼ Sell | Open Market | 940 | $249K | 2/8/2023 | View on chart |
| INSP | ▼ Sell | Open Market | 1,560 | $421K | 2/8/2023 | View on chart |
| INSP | ▼ Sell | Open Market | 490 | $122K | 2/6/2023 | View on chart |
| INSP | ▼ Sell | Open Market | 1,700 | $425K | 2/6/2023 | View on chart |
| INSP | ▼ Sell | Open Market | 949 | $238K | 2/6/2023 | View on chart |
| INSP | ▼ Sell | Open Market | 361 | $91K | 2/6/2023 | View on chart |
| INSP | ▼ Sell | Open Market | 1,170 | $300K | 1/3/2023 | View on chart |
| INSP | ▼ Sell | Open Market | 678 | $171K | 12/19/2022 | View on chart |
| INSP | ▲ Buy | Option Exercise | 6,218 | $6K | 9/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Starts Coverage of Inspire Medical with Underweight
Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.
Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.